Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of omalizumab on mast cells and basophils in chronic urticaria and atopic dermatitis
DRKS00003280Phase 4Completed
- Sponsor
- University Hospital Magdeburg
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of omalizumab in chronic urticaria (CU) and atopic dermatitis (AD) (2 cohorts), sponsored by University Hospital Magdeburg. Primary endpoints: Change in composition of intracellular granules of skin mast cells, Change in degranulation threshold of skin mast cells and 1 more. Started Oct 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic urticaria (CU)atopic dermatitis (AD)
Beyond the preview
Go deeper on DRKS00003280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003280.